Tonghe Pharmaceuticals (300636.SZ): The active pharmaceutical ingredient Mirabegron has received FDA registration approval.

Zhiyuan Finance APP News, Tonghe Pharmaceutical (300636.SZ) announced that the company recently received the U.S. Food and Drug Administration (hereinafter referred to as "FDA") issued Mirabegron Active Pharmaceutical Ingredient Registration Approval Letter DMF No Further Comments Letter (hereinafter referred to as "NFC Letter"). Mirabegron is a selective 3-adrenoceptor agonist that can enhance bladder capacity and storage ability by activating 3-adrenoceptors on the bladder detrusor muscle, and is clinically used to treat symptoms of overactive bladder such as urgency incontinence, urinary urgency, and frequency.